Effektivnost' i perenosimost' metotreksata pri psoriaticheskom artrite
- Authors: Badokin V.V1
-
Affiliations:
- Issue: No 19 (2012)
- Pages: 45-51
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/280060
- ID: 280060
Cite item
Open Access
Access granted
Abstract
The article presents the data on the main types of the course of psoriatic arthritis (PA), and discusses common approaches to the treatment of this disease. The place of methotrexate (MTX) in the treatment of psoriasis and PA is considered. The main indications for the administration of disease-modifying anti-rheumatic drugs for the treatment of the MT are malignant form of the PA, aggressive type of the disease, generalized joint disease, high laboratory activity, exudative, pustular or erithrodermic psoriasis, pronounced trophic disorders, persistent diffuse glomerulonephritis, low efficiency and poor tolerance of NSAIDs and glucocorticoids. The use of MTX for several months or even years (“involuntarily long-term use") allows monitoring the activity of PA and course of its major syndromes, reducing the progression of the disease, contributing to the preservation of working capacity of patients and improving their quality of life. The safety of use of MTX is discussed in detail.
Full Text
References
- Gladman D.D., Antoni C., Mease P., et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(2) :ii 14-7.
- Buckley C., Cavill C., Taylor G., et al. Mortality in psoriatic arthritis - a single-center study from the UK. J Rheumatol 2010;37:2141-44.
- Gladman D.D. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008;26:S62-65.
- Gladman D.D., Mease P.J., Strand V., et al. Consensus on a core set of domains for psoriaticarthritis. J Rheumatol 2007;34(5): 1167-70.
- Ritchlin C.T., Kavanaugh A., Gladman D.D., et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
- Kalb R.E., Strober B., Weinstein G., Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60: 824-37.
- Gossec L., Smolen J.S., Gaujoux-Viala C., et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
- Насонов Е.Л. Метотрексат. Перспективы применения в ревматологии. М., 2005.
- Cronstein B.N. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-55.
- Schwartz P.M., Barnett S.K., Atillasoy E.S., et al. Methotrexate induces differentiation of human keratinocytes. Proc Natl Acad Sci USA 1992;89:594-98.
- Solganick J., Tan M-H., Lebwohl M. A guide to systemic psoriasis treatment: methotrexate. Psoriasis Forum 2000;6:4-5.
- Menter A., Korman N.J., Elmets C.A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.
- Black R.L., O'Brien W.M., van Scott E.G., et al. Methotrexate therapy in psoriatic arthritis: double blind study on 21 patients. JAMA 1964;189:743-47.
- Willkens R.F., Williams H.J., Ward J.R., et al. Randomized, double-blind, placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
- Jones G., Crotty M., Brooks P. Interventious for psoriatic arthritis. Cochrane Database Syst Rev 2000;3:CD0002.
- Marguerie L., Flipo R.M., Grasdel B., et al. Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine 2002;69:275-81.
- Fraser A.D., van Kuijk A.W.R., Westhovens R., et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64(6):859-64.
- Wolf J., Stranzel T., Filipits M., et al. Expression of resistance markers to methotrexate predict clinical improvement in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64:564-68.
Supplementary files
